You searched for Gout - ACR Meeting Abstracts

Abstract Number: 0133 • ACR Convergence 2024
The Association Between Gout and Gallstone Disease: US General Population Analysis
Chio Yokose¹, Bohang Jiang², Natalie McCormick², Sharan Rai² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout is associated with kidney stones, but its association with gallstone disease is not known. Gout and gallstone disease have several shared risk factors…
Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0153 • ACR Convergence 2024
Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review
Kara Irwin, Ran Huo, Claire Barber and Cheryl Barnabe, University of Calgary, Calgary, AB, Canada
Background/Purpose: Despite advances in the management of inflammatory arthritis (IA) and gout, many patients still access acute care services. This may be related to their…
Abstract Number: 0178 • ACR Convergence 2024
Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?
Jendy Liu, Gregory Gamble and Nicola Dalbeth, University of Auckland, Auckland, New Zealand
Background/Purpose: Ensuring study participants are representative of the general population is important to ensure that efficacy and safety findings of clinical trials are generalizable in…
Abstract Number: 0206 • ACR Convergence 2024
Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout
May Shuen Tang, Frank Sen Hee Tay, Amelia Santosa, Shikha Kumari, Pamela Lim, Htet Htet Aung, Su Zin Thinn, Peter Cheung and Manjari Lahiri, National University Hospital, Singapore, Singapore
Background/Purpose: Gout is sub-optimally managed with under-prescribed urate lowering therapy (ULT) leading to frequent flares, increased healthcare utilization and cost.To study the burden of gout…
Abstract Number: 0265 • ACR Convergence 2024
Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Dansoa Tabi-Amponsah¹, Michael Doherty², Aliya Sarmanova³, Weiya Zhang², Sarah Stewart⁴, William Taylor⁵, Lisa Stamp⁶ and Nicola Dalbeth⁷, ¹The University of Auckland, Auckland, New Zealand, ²Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, ³Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, ⁴Auckland University of Technology, Auckland, New Zealand, ⁵The University of Otago, Wellington, Wellington, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand
Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0267 • ACR Convergence 2024
IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
Hong Di¹, Xinxin Han¹, Yun Zhang² and Xuejun Zeng¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital (CAMS), Beijing, China
Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
Abstract Number: 0268 • ACR Convergence 2024
Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Jie Wei¹, Yilun Wang², Nicola Dalbeth³, Junqing Xie⁴, Jing Wu⁵, Chao Zeng⁶, Guanghua Lei⁷ and Yuqing Zhang⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³University of Auckland, Auckland, New Zealand, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
Abstract Number: 0271 • ACR Convergence 2024
Intercritical Gout Represents a Systemic Inflammatory State
Tanner Ourada¹, Austin Wheeler², Michael Duryee², Bryant England², Richard Reynolds³, James O'Dell², Jeff Newcomb², Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls², ¹University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
Abstract Number: 0273 • ACR Convergence 2024
Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study
Elizabeth Lopez¹, Lesley Jackson², Kenneth Saag³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Montgomery, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Many people with gout utilize the emergency department (ED) for acute gout care, but many do not receive subsequent adequate outpatient care for long-term…
Abstract Number: 0274 • ACR Convergence 2024
Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Yana Pryymachenko¹, Ross Wilson¹, Haxby Abbott¹, Nicola Dalbeth² and Lisa Stamp³, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Songping Li⁸, Songbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), ⁶Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 0283 • ACR Convergence 2024
Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Jaymin Shah, Elaine Chan and Dmitri Lissin, Scilex Holding Company, Palo Alto, CA
Background/Purpose: Patients receiving colchicine for prophylaxis of gout flares are at risk for dose-related gastrointestinal toxicity (nausea, vomiting, diarrhea, abdominal pain) if they have pre-existing…

The Association Between Gout and Gallstone Disease: US General Population Analysis

The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis

Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?

Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout

Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care

Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol

IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis

Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study

Intercritical Gout Represents a Systemic Inflammatory State

Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study

Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout

Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study

Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform

Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model

Simple Search Results